2. Search Result
Search Result
Results for "

oxytocin receptors

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

24

Peptides

1

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108677
    L-368,899 hydrochloride
    Maximum Cited Publications
    7 Publications Verification

    		 Oxytocin Receptor Endocrinology
    L-368,899 hydrochloride is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC50s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively. L-368,899 hydrochloride used as a tocolytic agent .
    L-368,899 hydrochloride
  • HY-17572
    Atosiban
    Maximum Cited Publications
    7 Publications Verification

    RW22164; RWJ22164

    		 Oxytocin Receptor Vasopressin Receptor Cardiovascular Disease Endocrinology Cancer
    Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research .
    Atosiban
  • HY-17573
    Carbetocin
    2 Publications Verification

    		 Oxytocin Receptor Neurological Disease Endocrinology
    Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .
    Carbetocin
  • HY-124733A
    LIT-001

    		Oxytocin Receptor Neurological Disease
    LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism .
    LIT-001
  • HY-P3467
    (Thr4,Gly7)-Oxytocin
    3 Publications Verification

    		 Oxytocin Receptor Potassium Channel Neurological Disease
    (Thr4,Gly7)-Oxytocin, an Oxytocin analogue, is a specific OT receptor agonist. (Thr4,Gly7)-Oxytocin also excites subicular neurons via activation of TRPV1 channels, and depression of K + channels. .
    (Thr4,Gly7)-Oxytocin
  • HY-15023
    Cligosiban
    5+ Cited Publications

    PF-3274167

    		 Oxytocin Receptor Endocrinology
    Cligosiban (PF-3274167) is an orally active, highly selective, and centrally permeable oxytocin receptor antagonist with good pharmacokinetics in rats and can inhibit physiological ejaculation in rodents [1][2].
    Cligosiban
  • HY-15522
    WAY-267464
    2 Publications Verification

    		 Oxytocin Receptor Neurological Disease
    WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464
  • HY-W048739
    Fmoc-α-Me-Leu-OH

    		Amino Acid Derivatives Others
    Fmoc-α-Me-Leu-OH is a leucine derivative with an Fmoc protecting group, which can be used to synthesize peptides with oxytocin receptor agonist activity .
    Fmoc-α-Me-Leu-OH
  • HY-15010
    L-371,257
    1 Publications Verification

    		 Oxytocin Receptor Vasopressin Receptor Cardiovascular Disease Endocrinology
    L-371,257 is an orally bioavailable, non-blood-brain barrier penetrant, selective and competitive antagonist of oxytocin receptor (pA2=8.4) with high affinity at both the oxytocin receptor (Ki=19 nM) and vasopressin V1a receptor (Ki=3.7 nM) .
    L-371,257
  • HY-17572A
    Atosiban acetate
    Maximum Cited Publications
    7 Publications Verification

    RW22164 acetate; RWJ22164 acetate

    		 Oxytocin Receptor Vasopressin Receptor Cardiovascular Disease Endocrinology Cancer
    Atosiban acetate (RW22164 acetate;RWJ22164 acetate) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research .
    Atosiban acetate
  • HY-17573A
    Carbetocin acetate
    2 Publications Verification

    		 Oxytocin Receptor Neurological Disease Endocrinology
    Carbetocin acetate, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin acetate has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin acetate has the potential for postpartum hemorrhage research. Carbetocin acetate can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .
    Carbetocin acetate
  • HY-W587861
    5β-Dihydroprogesterone
    1 Publications Verification

    5βDHP

    		 Oxytocin Receptor Endocrinology
    5β-Dihydroprogesterone (5βDHP) is the metabolite of Progesterone (HY-N0437). 5β-Dihydroprogesterone binds to oxytocin receptor, reduces the Oxytocin (HY-17571)-induced calcium signal transduction, thereby exhibiting the tocolytic activity .
    5β-Dihydroprogesterone
  • HY-P0004
    Lysipressin
    2 Publications Verification

    Lysine vasopressin; [Lys8]-Vasopressin

    		 Adenylate Cyclase Oxytocin Receptor Cardiovascular Disease Neurological Disease
    Lysipressin (Lysine vasopressin) is antidiuretic hormone that have been found in pigs. Lysipressin activates Oxytocin receptors and adenylate-cyclase. Lysipressin adjusts blood pressure and heart rate. Lysipressin shows antinociceptive activity .
    Lysipressin
  • HY-108679
    WAY-267464 hydrochloride
    2 Publications Verification

    		 Oxytocin Receptor Neurological Disease
    WAY-267464 (hydrochloride) is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 (hydrochloride) can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 (hydrochloride) can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464 hydrochloride
  • HY-14778
    Retosiban

    GSK 221149; GSK 221149A

    		 Oxytocin Receptor Neurological Disease Endocrinology
    Retosiban (GSK221149A) is a potent, selective, and orally active oxytocin receptor antagonist (Ki (hOT) = 0.65 nM, Ki (rOT) = 4.1 nM) with no detectable agonist activity. Retosiban has nanomolar affinity for the oxytocin receptor with >1400-fold selectivity over the closely related vasopressin receptors. Retosiban inhibits spontaneous and induces uterine contractions. Retosiban can be studied in research for preterm labour .
    Retosiban
  • HY-153963
    PF-06655075

    		Oxytocin Receptor Endocrinology
    PF-06655075 is a novel andnon–brain-penetrant oxytocin receptor agonist with increased selectivity for the oxytocin receptor and significantly increased pharmacokinetic stability. PF-06655075 can be used as a tool compound to further explore the role of peripheral oxytocin in behavioral response .
    PF-06655075
  • HY-108678
    TC OT 39

    		Oxytocin Receptor Vasopressin Receptor Neurological Disease
    TC OT 39 is a synthetic oxytocin analog, as well as a selective agonist of oxytocin receptor (OXTR, EC50=180 nM). TC OT 39 is also an Avprla vasopressin receptor antagonist with an Ki value of 330 nM. TC OT 39 exhibits sedative effects in mouse models .
    TC OT 39
  • HY-128351
    SHR1653
    1 Publications Verification

    		 Oxytocin Receptor Neurological Disease Endocrinology
    SHR1653 is a highly potent, selective and brain penetrated oxytocin receptor (OTR) antagonist, with an IC50 of 15 nM for hOTR .
    SHR1653
  • HY-P1390
    d[Cha4]-AVP

    		Vasopressin Receptor Endocrinology
    d[Cha4]-AVP is a potent and selective vasopressin (AVP) V1b receptor agonist with a Ki of 1.2 nM for human V1b receptor. d[Cha4]-AVP shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors .
    d[Cha4]-AVP
  • HY-P4397
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin

    		Oxytocin Receptor Endocrinology
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin, an oxytocin receptor antagonist, abolishes oxytocin-enhanced inhibitory postsynaptic currents in CA1 pyramidal neurons .
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin
  • HY-P2626
    [D-Ala2]-Met-Enkephalin

    		Opioid Receptor Neurological Disease
    [D-Ala2]-Met-Enkephalin, an opioid peptide, is a potent opioid agonist. [D-Ala2]-Met-Enkephalin inhibits ACh-induced and suckling-induced oxytocin (OT) release .
    [D-Ala2]-Met-Enkephalin
  • HY-P3516
    Barusiban

    FE-200440

    		 Oxytocin Receptor Endocrinology
    Barusiban (FE-200440) is an oxytocin receptor (OT-R) antagonist (Ki=0.8 nM), inhibits OT-induced contraction. Barusiban can be used in preterm labor (PTL), in vitro fertilisation (IVF) and infertility research .
    Barusiban
  • HY-15008
    L-368,899

    		Oxytocin Receptor Endocrinology
    L-368,899 is an orally active and selective OT (oxytocin ) receptor antagonist, with IC50s of 8.9 and 26 nM for uterus of rat and human, respectively. L-368,899 can cross the blood-brain barrier (BBB). L-368,899 inhibits oxytocin-stimulated uterine contractions in rats and can be used in study of preterm labor .
    L-368,899
  • HY-P4895
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin

    		Oxytocin Receptor Neurological Disease
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin
  • HY-16741
    Erlosiban

    OBE001

    		 Oxytocin Receptor Endocrinology
    Erlosiban (OBE001) is an orally active non-peptide type oxytocin receptor antagonist. Erlosiban inhibits the increase of intracellular calcium concentration, thereby reducing uterine smooth muscle contraction. Erlosiban can be used for research on premature birth and to improve embryo implantation and pregnancy rate in assisted reproductive technology (AR).
    Erlosiban
  • HY-105018
    Epelsiban

    GSK 557296

    		 Oxytocin Receptor Endocrinology
    Epelsiban (GSK 557296) is a potent, selective and orally bioavailable oxytocin receptor antagonist, with a pKi of 9.9 for human oxytocin receptor.
    Epelsiban
  • HY-P0077
    Merotocin

    		Oxytocin Receptor Endocrinology
    Merotocin is a selective, short-acting peptidic oxytocin receptor agonist. Merotocin can be used to support lactation .
    Merotocin
  • HY-P1390A
    d[Cha4]-AVP TFA

    		Vasopressin Receptor Endocrinology
    d[Cha4]-AVP TFA is a potent and selective vasopressin (AVP) V1b receptor agonist with a Ki of 1.2 nM for human V1b receptor. d[Cha4]-AVP TFA shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors .
    d[Cha4]-AVP TFA
  • HY-P10325
    Kalata B7

    		Vasopressin Receptor Oxytocin Receptor Cardiovascular Disease
    Kalata B7 is a cyclotide that can be isolated from Oldenlandia affinis DC (Rubiaceae) and possesses membrane-permeating capabilities. Kalata B7 is also a partial agonist of oxytocin and vasopressin V1a receptors .
    Kalata B7
  • HY-124733
    LIT-001 free base

    		Oxytocin Receptor Neurological Disease
    LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 free base improves social interaction in a mouse model of autism .
    LIT-001 free base
  • HY-172814A
    OT-R agonist 1 TFA

    		Oxytocin Receptor Vasopressin Receptor Neurological Disease
    OT-R agonist 1 TFA (compound 5) is an oxytocin receptor agonist with an EC50 of 0.39 nM. OT-R agonist 1 TFA shows V1A antagonist activity with an EC50 of 2432 nM and can be used for study of CNS disorders .
    OT-R agonist 1 TFA
  • HY-P2034
    Cargutocin

    		Oxytocin Receptor Endocrinology
    Cargutocin, an oxytocin analogue, targets the oxytocin receptor and acts as a uterine contraction agent .
    Cargutocin
  • HY-124391
    L 156373

    		Oxytocin Receptor Endocrinology
    L 156373 is a potent oxytocin receptor antagonist with Ki value of 150 nM .
    L 156373
  • HY-153963A
    PF-06655075 TFA

    		Oxytocin Receptor Endocrinology
    PF-06655075 (TFA) is the TFA form of PF-06655075 (HY-153963). PF-06655075 is a novel andnon–brain-penetrant oxytocin receptor agonist with increased selectivity for the oxytocin receptor and significantly increased pharmacokinetic stability. PF-06655075 can be used as a tool compound to further explore the role of peripheral oxytocin in behavioral response .
    PF-06655075 TFA
  • HY-153964
    PF-06478939

    		Oxytocin Receptor Cardiovascular Disease
    PF-06478939 is a non-brain-penetrating peptide that is an agonist at oxytocin (OT) receptor and vasopressin receptor with EC50 values of 0.01 nM and 0.078 nM, respectively .
    PF-06478939
  • HY-153964A
    PF-06478939 TFA

    		Oxytocin Receptor Cardiovascular Disease
    PF-06478939 TFA is a non-brain-penetrating peptide that is an agonist at oxytocin (OT) receptor and vasopressin receptor with EC50 values of 0.01 nM and 0.078 nM, respectively .
    PF-06478939 TFA
  • HY-15023R
    Cligosiban (Standard)

    PF-3274167 (Standard)

    		 Oxytocin Receptor Reference Standards Endocrinology
    Cligosiban (Standard) is the analytical standard of Cligosiban. This product is intended for research and analytical applications. Cligosiban (PF-3274167) is an orally active, highly selective, and centrally permeable oxytocin receptor antagonist with good pharmacokinetics in rats and can inhibit physiological ejaculation in rodents .
    Cligosiban (Standard)
  • HY-129791
    L-367773

    		Oxytocin Receptor Endocrinology
    L-367773 is an orally active, selective oxytocin receptor antagonist, with Ki values of 26 nM and 61 nM for rat uterine oxytocin receptor and human uterine oxytocin receptor, respectively. L-367773 inhibits Oxytocin-stimulated uterine contractions .
    L-367773
  • HY-P4994
    Val9-Oxytocin

    		Vasopressin Receptor Cardiovascular Disease
    Val9-Oxytocin is a full antagonist of vasopressin (V1a) receptor. Val9-Oxytocin is an analog of Oxytocin (HY-17571A) in which changing Gly9 to Val9 .
    Val9-Oxytocin
  • HY-P5017
    (Val3,Pro8)-Oxytocin

    		Oxytocin Receptor Endocrinology
    (Val3,Pro8)-Oxytocin is the Gq-dependent pathway agonist. (Val3,Pro8)-Oxytocin is also a weaker agonist for the β-arrestin engagement and endocytosis toward the oxytocin receptor (OXTR) .
    (Val3,Pro8)-Oxytocin
  • HY-P4703
    Hydrin 1′

    		Oxytocin Receptor Others
    Hydrin 1′ is found in the neurohypophysis of Xenopus. Hydrin 1′ possesses a considerable steroid-releasing activity in Xenopus adrenal gland in vitro. Hydrin 1′ targets oxytocin receptor and derives a fluorescent probe of the oxytocin receptor .
    Hydrin 1′
  • HY-105018A
    Epelsiban besylate

    GSK 557296 benzenesulfonate

    		 Oxytocin Receptor Others
    Epelsiban Besylate (GSK 557296 benzenesulfonate) is an orally active compound known for its highly selective oxytocin receptor antagonist.
    Epelsiban besylate
  • HY-15018A
    SSR126768A free base

    		Oxytocin Receptor Endocrinology
    SSR126768A free base is an orally active antagonist for oxytocin receptor, with Ki of 0.44 nM. SSR126768A free base is a tocolytic agent, that antagonizes the Oxytocin (HY-17571)-induced intracellular Ca 2+ increase and prostaglandin release in human uterine smooth muscle cells, inhibits thus the Oxytocin (HY-17571)-induced uterine contraction and delays parturition in pregnant rats in labor .
    SSR126768A free base
  • HY-17572R
    Atosiban (Standard)

    RW22164 (Standard); RWJ22164 (Standard)

    		 Reference Standards Oxytocin Receptor Vasopressin Receptor Endocrinology Cancer
    Atosiban (Standard) is the analytical standard of Atosiban. This product is intended for research and analytical applications. Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research .
    Atosiban (Standard)
  • HY-17572AR
    Atosiban acetate (Standard)

    RW22164 acetate (Standard); RWJ22164 acetate (Standard)

    		 Reference Standards Oxytocin Receptor Vasopressin Receptor Endocrinology Cancer
    Atosiban (acetate) (Standard) is the analytical standard of Atosiban (acetate). This product is intended for research and analytical applications. Atosiban acetate (RW22164 acetate;RWJ22164 acetate) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research .
    Atosiban acetate (Standard)
  • HY-118918
    YM218 free base

    		Vasopressin Receptor Endocrinology
    YM218 free base is an orally active non-peptide vasopressin (AVP) receptor antagonist. YM218 free base has a high affinity for rat liver V1A receptors with a Ki value of 0.50 nM; it has a lower affinity for rat pituitary V1B, kidney V2, and uterine oxytocin receptors with Ki values of 1510 nM, 72.2 nM, and 150 nM, respectively. YM218 free base can be used in the study of diabetes and kidney disease .
    YM218 free base
  • HY-168742
    V1a/V2 antagonist 1

    		Vasopressin Receptor Neurological Disease
    V1a/V2 antagonist 1 (Compound 18j) is an orally active dual V1a and V2 receptor antagonist with high binding affinity for both receptors (Ki: 0.13 nM for hV1a, 0.53 nM for hV2 and 0.5 nM for mV1a; IC50: 2.2 nM for hV1a). V1a/V2 antagonist 1 inhibits Oxytocin (HY-17571)-induced scratching behavior in mice .
    V1a/V2 antagonist 1
  • HY-117637
    ALS-I-41

    		Oxytocin Receptor Neurological Disease
    ALS-I-41 is a novel, potent and selective oxytocin receptor antagonist with the potential to modulate biological activities related to social behavior and mental disorders. ALS-I-41 is being evaluated for behavioral pharmacology experiments in non-human primates and can be administered via intranasal or intramuscular injection. The central nervous system penetration and metabolic rate of ALS-I-41 were studied by mass spectrometry analysis in cerebrospinal fluid and plasma of macaque monkeys .
    ALS-I-41
  • HY-15007
    L 366509

    		Oxytocin Receptor Endocrinology
    L 366509 is a spiroindenylpiperidine camphorsulfonamide oxytocin (OT) antagonist. Modifications led to a new series of o-tolylpiperazine (TP) camphorsulfonamides, exhibiting high affinity for OT receptors and selectivity over arginine vasopressin receptors. Notably, compound 7 (L-368,899) showed excellent OT receptor affinity, potency in inhibiting OT-stimulated uterine contractions, good aqueous solubility, and oral bioavailability in multiple species. Compound 7 has entered clinical testing as an oral and intravenous tocolytic agent. Molecular modeling suggests the TP camphorsulfonamide structure mimics the D-AA2-Ile3 dipeptide, crucial in potent OT antagonists .
    L 366509
  • HY-108677R
    L-368,899 hydrochloride (Standard)

    		Reference Standards Oxytocin Receptor Endocrinology
    L-368,899 hydrochloride (Standard) is the analytical standard of L-368,899 hydrochloride (HY-108677). This product is intended for research and analytical applications. L-368,899 hydrochloride is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC50s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively. L-368,899 hydrochloride used as a tocolytic agent .
    L-368,899 hydrochloride (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: